Skip To Main Content

Financial Assistance Options

9 out of 10 patients are covered by insurance for VABYSMO®

No matter what type of health insurance you have, you may have options to help you afford your medicine. Options may be available to you even if you have no health insurance at all. The current price of VABYSMO is $2,233.80 per treatment*, but most people will not pay this amount. The amount you pay for VABYSMO depends on a variety of factors, including your insurance coverage.

*As of July 2024.

Get Started with Financial Assistance Tool

Use our financial assistance tool to see which programs may be right for you.

Get started

If you would rather talk through some potential options, call us at 866-4ACCESS (866-422-2377) (6AM-5PM PST, Monday through Friday).


Help With Co-pay Costs

These groups may help you pay for VABYSMO if you have insurance but still need help with costs:

Help With Costs for VABYSMO

Co-pay Card Assistance

With the Genentech Ophthalmology Co-pay Program, eligible patients with commercial insurance could pay as little as $0 per treatment. Co-pay assistance of up to $15,000 is provided per calendar year.

You may be eligible if you:

  • Are taking VABYSMO for an FDA-approved use
  • Are 18 years of age or older or have a Legally Authorized Person over the age of 18 to manage the program
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
  • Live and receive treatment in the United States or U.S. Territories
  • Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
  • Do not use a state or federal healthcare plan to pay for your medication. This includes, but is not limited to, Medicare, Medicaid and TRICARE

Help With Costs for Administration

Co-pay Card Assistance

With the Genentech Ophthalmology Co-pay Program, eligible patients with commercial insurance could pay as little as $0 per VABYSMO injection. Co-pay assistance is provided up to $1,000 per calendar year.

You may be eligible if you:

  • Are taking VABYSMO for an FDA-approved use
  • Are 18 years of age or older or have a Legally Authorized Person over the age of 18 to manage the program
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
  • Live and receive treatment in the United States or U.S. Territories
  • Are not receiving assistance from any charitable organization for the same expenses covered by the program*
  • Do not use a state or federal healthcare plan to pay for your therapy. This includes, but is not limited to, Medicare, Medicaid and TRICARE
  • Do not live or get treatments in certain states (Massachusetts or Rhode Island)

*Patients may use the Genentech Ophthalmology Co-pay Program for their administration costs if they are receiving their medicine from the Genentech Patient Foundation.

The Product and Administration Co-pay Programs (“Programs”) are valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. Patients using Medicare, Medicaid or any other federal or state government program (collectively, “Government Programs”) to pay for their Genentech medicine and/or administration services are not eligible.

Under the Programs, the patient may be required to pay a co-pay for drug costs and a co-pay for administration costs. The final amount owed by a patient may be as little as $0 for the Genentech medicine or administration of the Genentech medicine (see Program specific details available at the Program website). The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Programs assist with the cost of the Genentech medicine and the Genentech medicine administration only. It does not assist with the cost of other administrations, medicines, procedures or office visit fees. After reaching the maximum Programs’ benefit amounts, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the Programs’ benefits cannot exceed the patient’s out-of-pocket expenses for the cost of the Genentech medicine or administration fees for the Genentech medicine.

All participants are responsible for reporting the receipt of all Programs’ benefits as required by any insurer or by law. The Programs are only valid in the United States and U.S. Territories and are void where prohibited by law. The Drug Co-pay Program shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The Administration Co-pay Program is not valid for Massachusetts or Rhode Island residents. No party may seek reimbursement for all or any part of the benefit received through the Programs. The value of the Programs is intended exclusively for the benefit of the patient. The funds made available through the Programs may only be used to reduce the out-of-pocket costs for the patient enrolled in the Programs. The Programs are not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented programs that adjust patient cost-sharing obligations based on the availability of support under the Programs and/or excludes the assistance provided under the Programs from counting towards the patient’s deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Programs. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply from Genentech programs. Genentech reserves the right to rescind, revoke or amend the Programs without notice at any time.

Additional terms and conditions apply. Please visit the co-pay Program website for the full list of Terms and Conditions.

View full TERMS AND CONDITIONS

Patients may qualify for drug assistance, administration assistance or both, depending on whether they meet the eligibility criteria.

Independent Co-pay Assistance

An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance. Eligibility requirements, all aspects of the application process, turnaround times and the type or amount of assistance available (if any) can vary by foundation. 

These foundations may be able to help. Please check their websites for up-to-date information.

These organizations are independent of Genentech and may require you to provide personal or financial information directly to the organization to enroll in their respective programs. Genentech cannot share any information you have provided to us.

Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help you. We can only refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help you.


Genentech Patient Foundation

If you don’t have health insurance coverage or have financial concerns and meet eligibility criteria, this program may help:

Genentech Patient Foundation

The Genentech Patient Foundation gives free VABYSMO to people who have been prescribed this medicine and don’t have insurance or who have financial concerns and meet certain eligibility criteria.

You may be eligible if your insurance coverage and income match one of these situations:

  • Uninsured patients with incomes under $150,000
  • Insured patients without coverage for VABYSMO with incomes under $150,000
  • Insured patients with coverage for a Genentech medicine:
    • With an out-of-pocket maximum set by their health insurance plan that exceeds 7.5% of their household income
    • With household size and income within certain guidelines

For any of these situations, add $25,000 for each extra person in households larger than 4 people.

We encourage insured patients to try other financial assistance options before applying for help from the Genentech Patient Foundation, if possible.

Enrollment Process for the Genentech Patient Foundation

To get started:

  1. Complete the Patient Consent Form, which is available in English and Spanish, below:
  2. Once you have completed the Patient Consent Form, please let your doctor’s office know that you are applying for assistance with the Genentech Patient Foundation. Your doctor will have to complete another form called the Prescriber Foundation Form. Both forms are required. We must have both the Patient Consent Form and the Prescriber Foundation Form before we can help you.

What to expect next:

  • The request will be processed within five business days upon receipt of both required forms.
  • You and your provider will be contacted to discuss any next steps.

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

If you have any questions about the criteria, please contact a Foundation Specialist at 888-941-3331 (Mon.–Fri., 6AM–5PM PST).


Get Started with Financial Assistance Tool

Use our financial assistance tool to see which programs may be right for you.

Get started

  • Commercial insurance: An insurance plan you get from a private health insurance company. This can be insurance from your job, from a plan you bought yourself or from a Health Insurance Marketplace. Medicare and Medicaid are not considered commercial insurance.

  • Public insurance: A health insurance plan you get from the federal or state government. This includes Medicare, Medicaid, TRICARE and DoD/VA insurance.

  • We are open from 6AM-5PM PST, Mon. through Fri., except for the following holidays:

    • New Year’s Day
    • Martin Luther King, Jr. Day
    • Memorial Day
    • Juneteenth
    • Independence Day
    • Labor Day
    • Thanksgiving Holiday (Thursday and Friday)
    • Christmas Day
  • For example, a household size of 1 with income of less than $75,000 may meet the criteria for assistance. Add $25,000 for each additional person in the household. There is no maximum number of people you may add.

IMPORTANT SAFETY INFORMATION

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

  • Have an infection in or around your eye. 
  • Have active swelling around your eye that may include pain and redness. 
  • Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

  • Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
  • VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
  • Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
  • Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
  • Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
  • Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO? 

  • Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently. 

What are the most common side effects with VABYSMO?

  • The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
  • These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.